Lise Verhoef

Dr. Lise Verhoef

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2019 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
LVLise Verhoef
Lise Verhoef
BBBart Jf Van Den Bemt
Bart Jf Van Den Bemt
AMAatke Van Der Maas
Aatke Van Der Maas
JVJohanna E Vriezekolk
Johanna E Vriezekolk
MHMarlies E Hulscher
Marlies E Hulscher
ABAlfons A Den Broeder
Alfons A Den Broeder

16 January 2021 in Drugs
Verified
Journal Article
Open access
PDF file
CMC. A. J. Michielsens
C. A. J. Michielsens
MMM. E. van Muijen
M. E. van Muijen
LVLise Verhoef
Lise Verhoef
JRJ. M. P. A. van Den Reek
J. M. P. A. van Den Reek
EJE. M. G. J de Jong
E. M. G. J de Jong
Introduction Biologics serve as a cornerstone in psoriasis treatment, with low disease activity or sometimes even clinical remission as a realistic treatment outcome. So far, it is unclear whether biologics should be tapered when this target is achieved. Dose tapering could offer potential benefits by decreasing side effects, the burden of repetitive injections and costs of biological therapy. However, clinical guidelines on dose tapering of biologicals in psoriasis patients are lacking. This scoping review was conducted to provide an overview of the current literature on dose tapering and offer guidance for clinicians in daily clinical practice. Methods Dose tapering is defined as the administration of a lower dose per administration, or the prolongation of the regular dose interval, after initial treatment according to the standard dosing. Four electronic databases (PubMed, EMBASE, Cochrane, and Web of Science) were systematically searched for literature on tapering of biologics in adult patients with psoriasis from 1 January 2000. Results We included 19 original articles on biologic tapering in psoriasis patients: four randomized controlled trials and 15 observational studies. Tapering eligibility criteria, tapering strategies, tapering outcomes, and recapture of response after relapse were assessed. Furthermore, the available evidence on possible predictors for successful tapering, and the effect of tapering on safety, quality of life and costs is summarized. The definition of low disease activity as a measure for tapering eligibility varied widely. Beside tapering criteria, tapering strategies were also heterogeneous. Of note, quality-of-life measurements were barely integrated in the evaluation of tapering outcomes. Literature on regaining response after relapse due to tapering was limited, but restored remission has been described. The included studies did not proclaim a significant effect of tapering on the occurrence of (severe) adverse events. Even though cost savings have been reported, no proper cost-effectiveness analysis has been conducted yet. Conclusion Biologic tapering seems to be effective and safe in psoriasis patients with stable low disease activity or clinical remission. Available data on biologic dose tapering in patients with psoriasis are promising, but more research is warranted to fill the current gaps in knowledge.

2 March 2017 in Rheumatology and Therapy
Verified
Journal Article
Open access
PDF file
LVLise Verhoef
Lise Verhoef
LTLieke Tweehuysen
Lieke Tweehuysen
MHMarlies E. Hulscher
Marlies E. Hulscher
BFBruno Fautrel
Bruno Fautrel
ABAlfons A. Den Broeder
Alfons A. Den Broeder
Although bDMARDs are effective in the treatment of RA, they are associated with dose-dependent side effects, patient burden, and high costs. Recently, many studies have investigated the possibility of discontinuing or tapering bDMARDs when patients have reached their treatment goal. The aim of this review is to provide a narrative overview of the existing evidence on bDMARD dose reduction and to provide answers to specific dose-reduction-related questions that are of interest to clinicians.

15 January 2015 in Journal of Medical Internet Research
Verified
Journal Article
Open access
TBTom H van de Belt
Tom H van de Belt
LELucien Jlpg Engelen
Lucien Jlpg Engelen
LVLise Verhoef
Lise Verhoef
MWMarian Ja van der Weide
Marian Ja van der Weide
LSLisette Schoonhoven
Lisette Schoonhoven
RKRudolf B Kool
Rudolf B Kool
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

30 August 2017 in Trials
Verified
Journal Article
Open access
PDF file
ABAlfons A. Den Broeder
Alfons A. Den Broeder
LVLise Verhoef
Lise Verhoef
JFJaap Fransen
Jaap Fransen
RTRogier M Thurlings
Rogier M Thurlings
BBBart Van den Bemt
Bart Van den Bemt
FHFrank H. J. van Den Hoogen
Frank H. J. van Den Hoogen
A standard low-dosing schedule of rituximab (RTX; 2 × 500 mg or 1 × 1000 mg) is as effective for active rheumatoid arthritis (RA) as the registered dose (2 × 1000 mg). Moreover, several small uncontrolled studies suggest that even lower-dosed treatment with RTX also leads to good treatment response in patients with RA. Retreatment with such an ‘ultra-low’ dose RTX in patients who responded well to RTX induction treatment is of special interest, as long-term use of lower RTX doses may lead to shorter infusion duration, lower risk of adverse events and lower costs. However, the effect of ultra-low dose of RTX has not been investigated using a controlled trial of proper design and dimensions. REDO is an investigator driven six-month pragmatic, double-blind, randomised controlled non-inferiority trial on the effects of ultra-low-dose RTX (1 × 500 or 1 × 200 mg) compared to standard low dose (1 × 1000 mg) in RA patients who are being retreated with RTX. A total of 140 RA patients, having reached low disease activity (DAS28CRP < 2.9) after the previous RTX infusion and DAS28CRP < 3.5 at moment of retreatment, are randomised in a ratio of 1:2:2 to 1 × 1000 mg, 1 × 500 mg or 1 × 200 mg. The primary objective is testing non-inferiority of the ultra-low-dose vs. standard low-dose RTX, by comparing mean change in DAS28CRP from baseline to six months to the non-inferiority margin of 0.6. Secondary outcomes over the same period are: function; quality of life; safety; costs; and pharmacokinetics and dynamics as process measures. This study protocol shares characteristics of both early dose finding trials as well as late pragmatic clinical studies. Several choices in the design of this trial are described and possible consequences for RA treatment and expected biosimilar introduction are discussed. Dutch Trial Register, NTR6117 . Registered on 15 November 2016 (CMO NL57520.091.16 , 8 November 2016)

15 January 2020 in Trials
Verified
Journal Article
Open access
PDF file
CMCelia A. J. Michielsens
Celia A. J. Michielsens
NBNadine Boers
Nadine Boers
NBNathan Den Broeder
Nathan Den Broeder
MWMark H. Wenink
Mark H. Wenink
AMAatke van der Maas
Aatke van der Maas
ABAlfons A. Den Broeder
Alfons A. Den Broeder
Background: Tumour necrosis factor inhibitors (TNFi) are effective in the treatment of patients with spondyloarthritis (SpA), including psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). However, these drugs come with some disadvantages such as adverse events, practical burden for patients and high costs. Dose optimisation of TNFi after patients have reached low disease activity (LDA) has been shown feasible and safe in rheumatoid arthritis (RA). However, data on TNFi dose optimisation in PsA and axSpA are scarce, especially pragmatic, randomised strategy studies.Methods: We developed an investigator-driven, pragmatic, open-label, randomised, controlled, non-inferiority trial (DRESS-PS) to compare the effects of a disease activity-guided treat-to-target strategy with or without a tapering attempt in patients with SpA (PsA and axSpA combined), ≥ 16 years of age, who are being treated with TNFi, and have had at least 6 months of low disease activity. The primary outcome is the percentage of patients in LDA after 12 months of follow up. Patients are assessed at baseline, 3, 6, 9, and 12 months of follow up. Bayesian power analyses with a weakened prior based on a similar study performed in RA resulted in a sample size of 95 patients in total.Discussion: More knowledge on disease activity-guided treatment algorithms would contribute to better treatment choices and cost savings and potentially decrease the risk of side effects. In this article we elucidate some of our design choices on TNFi dose optimisation and its clinical and methodological consequences.Trial registration: Dutch Trial Register,NL6771. Registered on 27 November 2018 (CMO NL66181.091.18, 23 October 2018).